Lesson plan
U0126
U0126 is a MEK1/2 inhibitor that is used to study MEK and related signaling pathways. This inhibitor is selective for both MEK1 and MEK2, two specific types of MEK (MAPK kinases) that are elements of the MAPK/ERK signaling pathway. This compound is usually studied in the context of cancer treatment, ischemia, and cellular oxidative stress. The compound is not approved by the FDA as a therapeutic agent, and is primarily used in preclinical research settings. This compound is available for research purposes from a number of companies. U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with IC 50 of 72 nM for MEK1 and 58 nM for MEK2. U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways. U0126 is selective for MEK and has little to no effect on other signaling molecules such as PKC, Raf, ERK, JNK, MEKK, MKK-3, MKK-4/SEK, MKK-6, Cdk2 and Cdk4. The effects of U0126 on the growth of eight human breast cancer cell lines shown that U0126 selectively repressed anchorage-independent growth of MDA-MB231 and HBC4 cells, two lines with constitutively activated ERK.…
Article summary
U0126 is a MEK1/2 inhibitor that is used to study MEK and related signaling pathways. This inhibitor is selective for both MEK1 and MEK2, two specific types of MEK (MAPK kinases) that are elements of the MAPK/ERK signaling pathway. This compound is usually studied in the context of cancer treatment, ischemia, and cellular oxidative stress. The compound is not approved by the FDA as a therapeutic agent, and is primarily used in preclinical research settings. This compound is available for research purposes from a number of companies. U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with IC 50 of 72 nM for MEK1 and 58 nM for MEK2. U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways. U0126 is selective for MEK and has little to no effect on other signaling molecules such as PKC, Raf, ERK, JNK, MEKK, MKK-3, MKK-4/SEK, MKK-6, Cdk2 and Cdk4. The effects of U0126 on the growth of eight human breast cancer cell lines shown that U0126 selectively repressed anchorage-independent growth of MDA-MB231 and HBC4 cells, two lines with constitutively activated ERK.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.